NEWTOWN, Pa.--(BUSINESS WIRE)--March 7, 2005--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that the United States Patent and Trademark Office has issued a Notice of Intent to Issue a Reexamination Certificate confirming the patentability of certain amended claims of United States Patent RE 34,656 (the “‘656 Patent”), of which CollaGenex is the exclusive licensee. In the reexamination process, CollaGenex successfully demonstrated to the Patent Office that enhancement of bone protein synthesis using Periostat(R), a sub-antimicrobial dose of doxycycline, is patentable over all patents and publications identified in the reexamination. CollaGenex also overcame rejections based on double patenting over subject matter already covered in CollaGenex’s earlier ‘897 patent, which has now expired.
